The CSL (ASX:CSL) share price is down 9% in a month, here's why

This biotech giant's shares have been out of form recently…

| More on:
asx share price fall represented by woman shrugging

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has been a poor performer over the last few weeks.

Since this time last month, the biotherapeutics company's shares are down 9%.

This compares to a 1.5% gain by the S&P/ASX 200 Index (ASX: XJO) over the same period.

Why is the CSL share price out of form?

The weakness in the CSL share price over the last 30 days appears to have been driven by a couple of mixed broker notes.

One of those came from the team at Citi on 23 June. Its analysts downgraded CSL shares to a neutral rating from buy on valuation grounds following a period of outperformance. Citi held firm with its $310.00 price target.

A few days later CSL was hit with another broker downgrade. This time it came from the team at Credit Suisse. According to that note, its analysts downgraded CSL's shares to a neutral rating and cut the price target on them to $310.00.

Credit Suisse made the move on the belief that the market had not taken into account potential margin weakness caused by tough plasma collection conditions. It suspects that the recovery could take longer than expected due to continued pressure on collections, particularly after the US prevented Mexicans from crossing the border to donate.

The broker suspects that the gross margin of its CSL Behring business could fall to 54.1% in FY 2022. This compares to 61.2% in FY 2020.

Is this a buying opportunity?

Given that the CSL share price has now fallen to $277.72, the price targets of both Citi and Credit Suisse offer decent upside of 11.5% over the next 12 months.

In addition, the team at UBS still have a buy rating and $330.00 price target on the company's shares. This implies potential upside of almost 19% over the next 12 months.

So, while the CSL share price has underperformed over the last 30 days, the next 30 could be more positive. Just as long as its full year results in August don't contain any nasty surprises.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »